The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 11000 participants.

Also called NCT03129490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 11,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03129490
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03129490. Randomized; single masking; primary purpose prevention. Start 2023-04-01 (actual); primary completion 2027-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
Acronym
DANNOAC-AF
Intervention (Drug)
Dabigatran Etexilate Oral Capsule
Intervention (Drug)
Rivaroxaban Oral Tablet
Intervention (Drug)
Edoxaban Oral Tablet
Intervention (Drug)
Apixaban Oral Tablet
Lead sponsor
Herlev and Gentofte Hospital (class: other)

Record details

Record id
cardio:ct-nct03129490
Content hash
6cf242b8a6d493476597e91eeb32eaa14231f9254b2251adcff9df3a030bc3df